Cyclobenzaprine very low dose - Tonix Pharmaceuticals

Drug Profile

Cyclobenzaprine very low dose - Tonix Pharmaceuticals

Alternative Names: cyclobenzaprine HCI; KRL-102; Low dose cyclobenzaprine sublingual tablets; TNX-102; TNX-102 SL; Tonmya; VLD-cyclobenzaprine

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vela Pharmaceuticals
  • Developer Tonix Pharmaceuticals Holding Corp
  • Class Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Post-traumatic stress disorders
  • Discontinued Fibromyalgia

Most Recent Events

  • 17 Oct 2017 Tonix Pharmaceuticals receives official minutes from a chemistry, manufacturing and controls guidance meeting with the US FDA for Post-traumatic stress disorder
  • 14 Sep 2017 Tonix Pharmaceuticals has patent protection for very low dose cyclobenzaprine sublingual tablets in Europe
  • 30 May 2017 Efficacy and adverse events data from the phase II AtEase trial in Post-traumatic stress disorder released by Tonix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top